The growing use of GLP-1 drugs has raised many questions within the scientific community regarding the approach adopted to tackle obesity and diabetes. The management of these conditions appears to go beyond simple lifestyle changes, moving toward more structured and “pharmacological” strategies.
This shift is particularly evident in the Middle East, where rising obesity rates have reached a level that is difficult to sustain from both a healthcare and social perspective. In many Gulf countries, obesity has moved from being a marginal condition to becoming a complex chronic disease, closely linked to other equally concerning conditions: type 2 diabetes, cardiovascular risk, and metabolic syndrome. Data shows steady growth, with a direct impact on both people’s quality of life and the resilience of healthcare systems, which are increasingly exposed to high costs and the management of related conditions.
In this context, GLP-1 receptor agonists have emerged as one of the most effective responses, delivering significant clinical results in weight loss and improvement of metabolic parameters. Their ability to act on appetite, blood glucose, metabolism and body weight has helped redefine expectations among both physicians and patients, opening a new phase in obesity treatment.
However, this therapeutic revolution brings with it a level of complexity that is often underestimated. Alongside the benefits, side effects, challenges in treatment adherence and the risk of weight regain after discontinuation highlight how pharmacological treatment alone is not sufficient to guarantee long-term results.
A new clinical need is therefore emerging: to support pharmacological therapy with a broader approach capable of sustaining metabolism over time and managing the critical aspects associated with these treatments.
In the Middle East, obesity has reached a structural dimension. In many Gulf countries, it affects a large share of the population and is directly linked to the rise of type 2 diabetes, cardiovascular diseases, and metabolic disorders. The data describes a scenario that requires continuous and coordinated intervention with 21,2% obesity and 33,1% overweight (Journal of Obesity, 2022)1 , as it impacts individual health, but also the ability of healthcare systems to effectively manage chronic diseases.
Today, obesity is (rightly) treated as a complex chronic disease. It is in fact a multifactorial condition, meaning that it depends on a combination of biological, environmental, and behavioral factors. In Gulf countries, several dynamics have contributed to the spread of overweight.
Consider, for example, rapid urbanization, changes in dietary habits, and reduced physical activity. All of these elements have accelerated the process and make it more difficult to intervene with traditional tools. This complexity also explains why many strategies based solely on diet and physical activity struggle to produce stable long-term results.
Differences across countries highlight how deeply rooted the phenomenon is. In Kuwait, for example, female obesity rates exceed 48% (and in some cases reach up to 55% of the population), while male rates are lower. Similar situations are observed in Saudi Arabia and the United Arab Emirates, where obesity prevalence continues to rise alongside increasing cardiometabolic risk.
The data analyzed also show that obesity plays a key role in the development of several cardiovascular diseases, including coronary heart disease, heart failure, and atrial fibrillation. At a global level, the proportion of cardiovascular diseases directly attributable to obesity varies significantly between 0.3% and 19.8% depending on the country.
Among these conditions, heart failure appears to be the most influenced by excess weight, accounting for approximately 11.5% of total cases. This is followed by atrial fibrillation at around 9%, and coronary heart disease at about 4%.
Geographical analysis shows that the burden of obesity-related cardiovascular diseases is particularly critical in countries such as Syria, Kuwait and Iraq, where high obesity prevalence amplifies the epidemiological impact of these conditions. Gender dynamics also show relevant disparities, with risk fractions ranging between 3.6% and 10.5% in men, while in women the impact is significantly higher, ranging from 4.7% up to 13.4%.2
This imbalance across population groups highlights the need for targeted strategies, as the issue does not follow a single dynamic and requires context-specific interventions.
The impact of obesity goes beyond the clinical dimension. In Gulf countries, the rise in weight-related conditions directly affects healthcare spending and the sustainability of public systems. Data from the World Obesity Federation indicate that by 2035, obesity could account for over 4% of GDP in the United Arab Emirates, with a total cost (direct and indirect) of23.21 billion dollars.3
The increase in cases of diabetes, cardiovascular diseases and metabolic syndrome places constant pressure on healthcare systems. Costs involve not only direct treatments, but also long-term monitoring, hospitalizations, and complication management. This scenario requires increasing resources and challenges the ability of systems to ensure continuity of care on a large scale.
Obesity also affects the productive sector. Associated conditions lead to increased absenteeism and reduced operational efficiency. In the long term, this translates into a loss of productivity that impacts the overall economy.
In recent years, obesity pharmacotherapy has introduced more effective tools compared to the past. GLP-1 receptor agonists, in particular, act on biological mechanisms that influence body weight, as they are linked to appetite regulation and metabolism.
So, what is GLP-1? It is a hormone produced by the intestine that regulates several metabolic processes. Drugs that mimic its action increase satiety, slow gastric emptying and help control blood glucose levels.
This combined action makes it possible to intervene more precisely on eating behaviour and metabolism, reducing caloric intake without resorting to drastic restrictions. The result is a more controlled weight loss and, in many cases, more sustainable over time.
Among the most commonly used molecules are semaglutide (Wegovy®, Ozempic®) and tirzepatide (Mounjaro®). The former acts as a GLP-1 agonist and has demonstrated in clinical trials a weight reduction of over 15%.4 The latter introduces a broader mechanism, as it also acts on the GIP receptor, producing a stronger effect on metabolism and appetite.
These drugs also act on visceral fat, which represents one of the main risk factors for cardiometabolic diseases. Their use, therefore, has an impact that goes beyond the number on the scale and involves broader clinical parameters related to overall metabolic health.
The effectiveness of GLP-1 drugs has led many healthcare systems to consider them a concrete tool in obesity management. Clinical results show significant improvements across several parameters, but real-world patient experience also highlights critical issues that affect treatment continuity. Understanding both aspects allows for a more complete evaluation of the role of these therapies.
The impact of these therapies is systemic. First of all, the effects of GLP-1 drugs on blood sugar are particularly relevant, as they have proven highly effective in glycemic control. They also reduce blood pressure and help rebalance the lipid profile. Some studies have shown a reduction in cardiovascular risk even in patients without diabetes, confirming an effect that goes beyond weight loss.
Their action on metabolism also involves the liver and visceral fat, with clinical benefits observed in patients with hepatic steatosis. This set of effects makes GLP-1 drugs important tools in managing cardiometabolic risk, especially in contexts where these conditions are widespread.
It is important to remember that the use of GLP-1 drugs involves side effects that influence the patient’s experience from the early stages of treatment. The most common issues affect the gastrointestinal tract and include nausea, vomiting, constipation and reflux. These symptoms tend to appear during dose escalation and may affect adherence to therapy.
Alongside the more common effects, there are less frequent but clinically relevant conditions such as pancreatitis and gallstones. Another aspect concerns the loss of muscle mass, which can accompany weight loss if not managed with adequate nutritional support and targeted physical activity.
Muscle loss is mainly caused by a strong caloric and protein deficit, combined with the activation of catabolic processes and a reduction in anabolic hormones (such as IGF-1). This phenomenon is exacerbated by a sedentary lifestyle and side effects such as nausea and early satiety, which further limit nutrient intake.
To preserve muscle mass and ensure healthy weight loss, the following are necessary:
There may also be effects of diabetes drugs on sex life, as treatment influences multiple dimensions of health.
Overall, these are significant side effects that require constant monitoring and careful management of the therapeutic pathway.
A significant proportion of patients discontinue treatment earlier than expected, often due to side effects, high drug costs or difficulty maintaining the therapeutic pathway over time. A recent population-based analysis in Denmark revealed that over 50% of patients initiated on GLP-1 receptor agonists, specifically semaglutide, ceased treatment within the first year.5
This interruption raises a central issue in obesity management: what happens after the drug is discontinued. The answer to this question becomes crucial in evaluating the real long-term effectiveness of the therapy.
Stopping GLP-1 drugs opens a delicate phase of the therapeutic pathway. During treatment, the drug modulates the signals that regulate hunger and satiety. When this support is removed, the balance built over time can change rapidly, and the patient must manage stronger physiological stimuli again.
Research from JAMA Internal Medicine (Nov 2025) shows that after 36 weeks on tirzepatide, patients who switched to a placebo struggled with weight maintenance. Within a year of stopping the drug, 82% of those who lost weight regained a quarter or more of it. Furthermore, as weight returned, the metabolic benefits—such as improved cholesterol and blood sugar levels—began to disappear.6
One of the most evident effects is the return of so-called “food noise,” meaning the constant thoughts related to food. Without the drug’s action, the sense of satiety decreases and appetite regulation returns to pre-treatment levels. This can lead to an increase in caloric intake and, over time, weight regain.
Another factor must be considered: during weight loss, part of lean mass may decrease. The loss of muscle mass and lean mass slows metabolism and makes it more difficult to maintain achieved results, especially without targeted nutritional and physical activity strategies.
To protect lean muscle mass, Cor.Con. International has developed a dietary supplement designed for individuals undergoing GLP-1 receptor agonist therapy. EuPower, formulated with creatine monohydrate, HMB (beta-hydroxy-beta-methylbutyrate), and vitamin D, should be combined with appropriate physical activity and adequate protein intake.
Pharmacological intervention acts on specific physiological mechanisms, but it does not automatically change habits, behaviours, and the context in which the metabolic condition develops.
When the therapeutic pathway relies only on the drug, maintaining results becomes more complex. This is why weight management requires an integrated approach that takes all these factors into account.
Managing obesity requires continuity over time. GLP-1 drugs act on specific mechanisms and deliver significant results, but the process does not end with pharmacological therapy. Side effects, metabolic adaptation, and the post-treatment phase require tools that support the patient beyond the therapy itself.
During treatment, many patients experience gastrointestinal issues, appetite changes, and shifts in body composition. These aspects affect quality of life and may lead to block treatment earlier than expected. In addition, the post-treatment phase exposes patients to the risk of regaining weight, especially if metabolism has not been adequately supported.
The work of Cor.Con. International focuses precisely on supporting pharmacological therapies through nutritional integration. The goal is to develop solutions for metabolic well-being through scientific research, clinical studies, and targeted formulations. Their supplements for the metabolic system support patients with specific substances to counteract the cellular effects of oxidative stress, but also to limit the absorption of lipids and fatty acids.
Integrating pharmacological therapy with metabolic support allows for a more stable pathway, where the patient does not rely on a single lever but can count on a broader and continuous strategy.
The spread of GLP-1 drugs in Gulf countries faces concrete limitations related to cost, availability, and healthcare system organization. Access to these therapies, in fact, remains uneven and often depends on the patient’s financial capacity or local health policies.
The high cost of these treatments represents one of the main barriers. Availability is also not always consistent: growing demand has created shortages that complicate treatment continuity.
Limited access has also encouraged the spread of unsafe alternative solutions, often lacking any prior clinical oversight. Some patients therefore turn to unregulated channels or non-certified preparations.
Advances in research are expanding treatment possibilities. In particular, new methods of administration are being explored, including oral formulations that eliminate the need for weekly injections.
In the coming years, the main objective will be to reduce costs in order to facilitate access to therapies. Wider availability of treatments could enable earlier intervention on cardiometabolic risk, with concrete benefits for public health and healthcare system sustainability.
Ultimately, the future of obesity management will depend on the ability to integrate pharmacological innovation, metabolic support, and long-term therapeutic continuity.
References